Ginsenoside Rg3 suppresses the proliferation of prostate cancer cell line PC3 through ROS-induced cell cycle arrest

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
• Ginsenosides, particularly Rg3, are being explored for their potential anticancer properties.

Purpose of the Study:

• To investigate the antitumor effects of ginsenoside Rg3 on the androgen-insensitive prostate cancer cell line PC3.
• To elucidate the underlying mechanisms of ginsenoside Rg3-induced cell cycle arrest.

Main Methods:

• In vitro culture of PC3 cells treated with ginsenoside Rg3.
• Cell proliferation assays, cell counting, and senescence-associated β-galactosidase staining.
• Flow cytometry for cell cycle analysis and reactive oxygen species (ROS) detection.
• N-acetyl-L-cysteine (ROS scavenger) pretreatment to assess mechanism.

Main Results:

• Ginsenoside Rg3 significantly reduced PC3 cell number and proliferation.
• Treatment induced cell cycle arrest at the G1/S transition and increased SA-β-gal staining.
• Ginsenoside Rg3 upregulated ROS levels in PC3 cells.
• ROS scavenging reversed the inhibitory effects of ginsenoside Rg3 on cell proliferation and cycle.

Conclusions:

• Ginsenoside Rg3 demonstrates anticancer potential against prostate cancer cells.
• The mechanism involves ROS-mediated cell cycle arrest at the G1/S phase.
• Ginsenoside Rg3 warrants further investigation as a therapeutic agent for prostate cancer.